{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:25:48Z","timestamp":1792013148101,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012868","name":"Lillehei Heart Institute, University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.amepre.2020.10.025","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T06:57:01Z","timestamp":1612508221000},"page":"513-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Aspirin Use and Misuse for the Primary Prevention of Cardiovascular Diseases"],"prefix":"10.1016","volume":"60","author":[{"given":"Russell V.","family":"Luepker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki C.","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Misialek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy R.","family":"Van't Hof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Finnegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.amepre.2020.10.025_bib0001","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.amepre.2014.11.005","article-title":"Aspirin use among adults in the U.S.: results of a national survey","volume":"48","author":"Williams","year":"2015","journal-title":"Am J Prev Med"},{"issue":"12","key":"10.1016\/j.amepre.2020.10.025_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002320","article-title":"Population trends in aspirin use for cardiovascular disease prevention 1980-2009: the Minnesota Heart Survey","volume":"4","author":"Luepker","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.amepre.2020.10.025_bib0003","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/pds.3463","article-title":"Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population","volume":"23","author":"Zhou","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.amepre.2020.10.025_bib0004","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.CIR.54.3.365","article-title":"Platelet aggregation in partially obstructed vessels and its elimination with aspirin","volume":"54","author":"Folts","year":"1976","journal-title":"Circulation"},{"issue":"9678","key":"10.1016\/j.amepre.2020.10.025_bib0005","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.amepre.2020.10.025_bib0006","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis [published correction appears in JAMA. 2019;321(22):2245]","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.amepre.2020.10.025_bib0007","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-136-2-200201150-00015","article-title":"Aspirin for the primary prevention of cardiovascular events: recommendation and rationale","volume":"136","year":"2002","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.amepre.2020.10.025_bib0008","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-150-6-200903170-00008","article-title":"Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement","volume":"150","year":"2009","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.amepre.2020.10.025_bib0009","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.amepre.2020.10.025_bib0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jacc.2014.10.035","article-title":"Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry","volume":"65","author":"Hira","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.amepre.2020.10.025_bib0011","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3821\/1913-701X-143.4.192","article-title":"Patient self-medication with ASA 81 mg","volume":"143","author":"Taylor","year":"2010","journal-title":"Can Pharm J"},{"issue":"1","key":"10.1016\/j.amepre.2020.10.025_bib0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2261-14-16","article-title":"Aspirin use and knowledge in the community: a population- and health facility based survey for measuring local health system performance","volume":"14","author":"Roth","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"10.1016\/j.amepre.2020.10.025_bib0013","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11606-014-2985-8","article-title":"Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?","volume":"30","author":"Fiscella","year":"2015","journal-title":"J Gen Intern Med"},{"issue":"10152","key":"10.1016\/j.amepre.2020.10.025_bib0014","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.amepre.2020.10.025_bib0015","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.amepre.2020.10.025_bib0016","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.amepre.2020.10.025_bib0017","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.amepre.2020.10.025_bib0018","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.119.040205","article-title":"Revisiting the role of aspirin for the primary prevention of cardiovascular disease","volume":"140","author":"Marquis-Gravel","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.amepre.2020.10.025_bib0019","doi-asserted-by":"crossref","first-page":"596","DOI":"10.7326\/M19-0953","article-title":"Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey","volume":"171","author":"O'Brien","year":"2019","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.amepre.2020.10.025_bib0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jama.2018.20577","article-title":"Aspirin for primary prevention: clinical considerations in 2019","volume":"321","author":"Gaziano","year":"2019","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.amepre.2020.10.025_bib0021","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMe1812000","article-title":"Should aspirin be used for primary prevention in the post-statin era?","volume":"379","author":"Ridker","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.amepre.2020.10.025_bib0022","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","article-title":"Aspirin for primary prevention of cardiovascular events","volume":"73","author":"Abdelaziz","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.amepre.2020.10.025_bib0023","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.amepre.2020.10.025_bib0024","series-title":"Behavioral Risk Factor Surveillance System: 2018 summary data quality report","year":"2019"},{"key":"10.1016\/j.amepre.2020.10.025_bib0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/CLEP.S219708","article-title":"Estimation of cardiovascular risk from self-reported knowledge of risk factors: insights from the Minnesota Heart Survey","volume":"12","author":"Duval","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.amepre.2020.10.025_bib0026","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2105\/AJPH.88.8.1230","article-title":"Trends in cigarette smoking: the Minnesota Heart Survey, 1980 through 1992","volume":"88","author":"Arnett","year":"1998","journal-title":"Am J Public Health"},{"issue":"4","key":"10.1016\/j.amepre.2020.10.025_bib0027","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1076029613486537","article-title":"Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement","volume":"20","author":"Zantek","year":"2014","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.amepre.2020.10.025_bib0028","unstructured":"American community survey (ACS). U.S. Census Bureau. https:\/\/www.census.gov\/programs-surveys\/acs. Accessed October 13, 2020."},{"issue":"22","key":"10.1016\/j.amepre.2020.10.025_bib0029","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"issue":"9759","key":"10.1016\/j.amepre.2020.10.025_bib0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.amepre.2020.10.025_bib0031","article-title":"Association of aspirin use with mortality risk among older adult participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial [published correction appears in JAMA Netw Open. 2020;3(1):e1921081]","volume":"2","author":"Loomans-Kropp","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.amepre.2020.10.025_bib0032","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amepre.2005.08.042","article-title":"Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System","volume":"30","author":"Ajani","year":"2006","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.amepre.2020.10.025_bib0033","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/CLEP.S72032","article-title":"Aspirin overutilization for the primary prevention of cardiovascular disease","volume":"6","author":"VanWormer","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.amepre.2020.10.025_bib0034","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2014.03.049","article-title":"Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis [published correction appears in J Am Coll Cardiol. 2014;64(18):1970]","volume":"64","author":"Halvorsen","year":"2014","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"10.1016\/j.amepre.2020.10.025_bib0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40360-015-0028-7","article-title":"Prevalence, trends, patterns and associations of analgesic use in Germany","volume":"16","author":"Sarganas","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.amepre.2020.10.025_bib0036","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/1741826710397850","article-title":"A national survey on aspirin patterns of use and persistence in community outpatients in Italy","volume":"18","author":"Filippi","year":"2011","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"2","key":"10.1016\/j.amepre.2020.10.025_bib0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ypmed.2007.08.006","article-title":"Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland","volume":"46","author":"Rodondi","year":"2008","journal-title":"Prev Med"},{"issue":"10","key":"10.1016\/j.amepre.2020.10.025_bib0038","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006328","article-title":"Contemporary primary prevention aspirin use by cardiovascular disease risk: impact of U.S. Preventive Services Task Force Recommendations, 2007-2015: a serial, cross-sectional study","volume":"6","author":"Van't Hof","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amepre.2020.10.025_bib0039","series-title":"National Health Interview Survey Early Release Program: wireless substitution: early release of estimates from the National Health Interview Survey, July\u2013December 2018","author":"Blumberg","year":"2019"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379721000179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379721000179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:59:48Z","timestamp":1760083188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379721000179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0749379721000179"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2020.10.025","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin Use and Misuse for the Primary Prevention of Cardiovascular Diseases","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2020.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}